A Braester1, L Akria, C Suriu, V Sonkin. Show Affiliations » 1. Institute of Hematology, Western Galilee Hospital, Nahariya, Israel. andrei.braester@naharia.health.gov.il
Abstract
Entities: Chemical Disease
Mesh： See more » AlemtuzumabAntibodies, Monoclonal, Humanized/adverse effectsAntibodies, Monoclonal, Humanized/therapeutic useAntineoplastic Agents/adverse effectsAntineoplastic Agents/therapeutic useHumansLeukemia, Lymphocytic, Chronic, B-Cell/drug therapyLeukemia, Lymphocytic, Chronic, B-Cell/pathologyMyelodysplastic Syndromes/chemically inducedMyelodysplastic Syndromes/pathology
Substances： See more » Antibodies, Monoclonal, HumanizedAntineoplastic AgentsAlemtuzumab
Year: 2012 PMID： 23257842 DOI： 10.1159/000345254
Source DB: PubMed Journal: Acta Haematol ISSN： 0001-5792 Impact factor: 2.195